SCHEMBL5352710

SCHEMBL5352710

N[C@@H](CO)CN1CCc2cc(F)ccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.48
HDAC1 Q13547 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
HTR2A P28223 7/20 0.43
HTR2C P28335 7/20 0.43
HTR2B P41595 7/20 0.43
CHRM2 P08172 1/20 0.42
CHRM3 P20309 1/20 0.42
KDM4A O75164 1/20 0.42
KDM2B Q8NHM5 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
CTSS P25774 2/20 0.41
NPY5R Q15761 1/20 0.41
CNR2 P34972 1/20 0.40
CTSL P07711 2/20 0.40
ROCK1 Q13464 1/20 0.39
CTSK P43235 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3024089 0.82 HTR2C (0.62) NOTUMHDAC1HDAC6HTR2AHTR2C
SCHEMBL905724 0.82 HTR2C (0.62) NOTUMHDAC1HDAC6HTR2AHTR2C
SCHEMBL5357052 0.80 NPY5R (0.46) NOTUMHDAC1HDAC6HTR2AHTR2C
SCHEMBL5357429 0.78 CTSL (0.48) NOTUMHDAC1HDAC6HTR2AHTR2C
SCHEMBL5118232 0.77 NOTUM (0.54) NOTUMHDAC1HDAC6CHRM2CHRM3
SCHEMBL3012389 0.76 CTSS (0.48) CTSSCTSLCTSK
SCHEMBL27667528 0.76 CTSS (0.48) CTSSCTSLCTSK
SCHEMBL3014379 0.74 NOTUM (0.46) NOTUMHDAC1HDAC6HTR2AHTR2C
SCHEMBL24823574 0.73 NOTUM (0.49) NOTUMHDAC1HDAC6HTR2CHTR2B
SCHEMBL12060492 0.73 NOTUM (0.53) NOTUMHDAC1HDAC6HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7307095-B2 Osteoporosis; antiarthritic agents; antidiabetic agents; antiinflammatory agents; Alzheimer's disease; shock; central nervous stsrem disorders; anticancer agents; multiple sclerosis, (S)-2-(Benzooxazol-2-ylamino)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide IRM LLC (BM) 2007-12-11 US claimed
US-20070123523-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2007-05-31 US claimed
US-7173051-B2 Inhibitors of cathepsin S IRM, LLC (BM) 2007-02-06 US claimed
US-20050049244-A1 Inhibitors of cathepsin S IRM LLC (BM) 2005-03-03 US claimed
WO-2004112709-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2004-12-29 WO claimed
US-7507755-B2 Inhibitors of cathepsin s IRM LLC (BM) 2009-03-24 US disclosed
US-7507755-B2 Inhibitors of cathepsin s IRM LLC (BM) 2009-03-24 US disclosed
US-7307095-B2 Osteoporosis; antiarthritic agents; antidiabetic agents; antiinflammatory agents; Alzheimer's disease; shock; central nervous stsrem disorders; anticancer agents; multiple sclerosis, (S)-2-(Benzooxazol-2-ylamino)-3-cyclohexyl-N-[2-(5-fluoro-2,3-dihydro-indol-1-yl)-ethyl]-propionamide IRM LLC (BM) 2007-12-11 US disclosed
US-20070259873-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2007-11-08 US disclosed
US-20070259873-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2007-11-08 US disclosed
US-7256207-B2 Inhibitors of cathepsin S IRM LLC (BM) 2007-08-14 US disclosed
US-7256207-B2 Inhibitors of cathepsin S IRM LLC (BM) 2007-08-14 US disclosed
US-20070123523-A1 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2007-05-31 US disclosed
US-7173051-B2 Inhibitors of cathepsin S IRM, LLC (BM) 2007-02-06 US disclosed
US-20050049244-A1 Inhibitors of cathepsin S IRM LLC (BM) 2005-03-03 US disclosed
WO-2005018568-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2005-03-03 WO disclosed
WO-2004112709-A2 INHIBITORS OF CATHEPSIN S IRM LLC (BM) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049244-A1 Inhibitors of cathepsin S CTSS, CTSB, CTSZ NOTUM 796/4885HDAC1 346/4885HDAC6 189/4885
US-20070259873-A1 INHIBITORS OF CATHEPSIN S CTSS, CTSB, CTSZ NOTUM 796/4885HDAC1 346/4885HDAC6 189/4885
US-20070123523-A1 INHIBITORS OF CATHEPSIN S CTSS, CTSB, CTSZ NOTUM 796/4885HDAC1 346/4885HDAC6 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.